Imel Biotherapeutics develops cell-based therapies to treat patients with mitochondrial disorders.
Imel Biotherapeutics has raised $15.0M in total funding. The most recent round was Series A. The last funding was announced in November 2021.
Imel Biotherapeutics is headquartered in Waltham, United States.
Imel Biotherapeutics develops cell-based therapies to treat patients with mitochondrial disorders.
Imel Biotherapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Imel Biotherapeutics — Funding & Investors." VCBacked, November 15, 2021, https://www.vcbacked.co/company/imel-biotherapeutics. Accessed August 14, 2026.
VCBacked. (2021). Imel Biotherapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/imel-biotherapeutics
{{cite web |title=Imel Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/imel-biotherapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated